Anthos Therapeutics announces that 1287 patients enrolled across 95 global study sites in the AZALEA-TIMI 71 Ph2 study evaluating the safety and tolerability of abelacimab compared to rivaroxaban Abelacimab is a monoclonal antibody with dual activity against Factor XI and Factor XIa administered monthly CAMBRIDGE, Mass., Dec. 7, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing […]